Alcon Sees Big Opportunity In Glaucoma Surgery; Buys Ivantis For $475M
Ivantis markets the Hydrus Microstent for minimally invasive glaucoma surgery, a field Alcon exited three years ago when it pulled its CyPass from the market
You may also be interested in...
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
Jeannette Bankes, the general manager of Alcon’s global surgical business, talked to Medtech Insight about how the company is addressing the cataract surgery market with a range of intraocular lenses intended to return the patients vision to as close to its natural optimal function as possible.
Rate adjustment recommendations to US Medicare could result in less drastic reimbursement cuts for Glaukos than those currently on the table.